You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: December 23, 2024

Details for Patent: 11,123,363


✉ Email this page to a colleague

« Back to Dashboard


Which drugs does patent 11,123,363 protect, and when does it expire?

Patent 11,123,363 protects VELTASSA and is included in one NDA.

This patent has eighteen patent family members in nine countries.

Summary for Patent: 11,123,363
Title:Potassium-binding agents for treating hypertension and hyperkalemia
Abstract: The present invention generally relates to methods of treating hypertension (HTN) in patients in need thereof wherein the patient optionally further suffers from chronic kidney disease (CKD) or Type II diabetes mellitus (T2DM). The invention also relates to methods of treating hyperkalemia in a patient in need thereof, wherein the patient suffers from CKD, T2DM or HTN and are optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The invention also relates to methods of treating kidney disease in a patient in need thereof, wherein the patient is optionally being treated with an effective amount of a renin-angiotensin-aldosterone system (RAAS) agent. The methods can comprise administering an effective amount of a potassium-binding agent to the patient to lower the patient's blood pressure and/or increase or stabilize the patient's kidney function.
Inventor(s): Klaerner; Gerrit (Los Gatos, CA), Berman; Lance (San Francisco, CA)
Assignee: VIFOR (INTERNATIONAL) LTD. (St. Gallen, CH)
Application Number:15/916,617
Patent Claim Types:
see list of patent claims
Use; Formulation;
Patent landscape, scope, and claims:

United States Patent 11,123,363: A Detailed Analysis of Scope, Claims, and Patent Landscape

Introduction

United States Patent 11,123,363, titled "Potassium-binding agents for treating hypertension and hyperkalemia," is a significant patent in the field of medical treatments, particularly for cardiovascular and renal diseases. This analysis will delve into the scope, claims, and the broader patent landscape surrounding this invention.

Background and Invention Overview

The patent, assigned to a pharmaceutical company, describes methods and compositions for treating hypertension (HTN) and hyperkalemia using potassium-binding agents. Hyperkalemia, a condition characterized by elevated potassium levels in the blood, can be life-threatening and often requires immediate medical attention. The invention provides a novel approach to managing this condition, which is crucial given the prevalence of cardiovascular diseases and the need for effective treatments.

Scope of the Invention

The scope of the invention is defined by the claims, which outline the specific methods, compositions, and uses of the potassium-binding agents. Here are some key aspects:

Claims Structure

The patent includes multiple claims that detail the invention's various aspects, such as:

  • Independent Claims: These claims define the broadest scope of the invention, including the composition of the potassium-binding agents and the methods for their use.
  • Dependent Claims: These claims narrow down the scope by specifying particular embodiments, such as specific types of potassium-binding agents or additional components in the composition[4].

Key Components

  • Potassium-Binding Agents: The patent specifies various agents, including fluoroacrylate and divinylbenzene crosslinked polymers, which are designed to bind potassium ions in the gastrointestinal tract, thereby reducing blood potassium levels.
  • Methods of Treatment: The claims include methods for administering these agents to patients suffering from hypertension and hyperkalemia, highlighting the therapeutic applications of the invention[4].

Claims Analysis

Claim 1: Composition Claims

Claim 1 typically sets the foundation for the invention by describing the composition of the potassium-binding agents. This includes the type of polymer, its crosslinking structure, and any additional components that enhance its efficacy.

Claim 2-5: Method Claims

Subsequent claims detail the methods of using these agents, including the dosage, administration route, and specific patient populations. These claims are crucial as they define how the invention can be practically applied in a clinical setting.

Dependent Claims: Specific Embodiments

Dependent claims further specify particular embodiments, such as the use of calcium as a counterion or the inclusion of other therapeutic agents to enhance the treatment's effectiveness. These claims help to protect specific aspects of the invention while allowing for flexibility in its application[4].

Patent Landscape

Technological Field

The patent falls under the broader category of pharmaceuticals and medical treatments, specifically within the field of cardiovascular and renal diseases. The technological field is highly competitive, with numerous patents and ongoing research in potassium-binding agents and other treatments for hyperkalemia.

Prior Art and Novelty

To be granted, the patent must demonstrate novelty and non-obviousness over prior art. The patent office would have reviewed existing patents and publications to ensure that the claimed invention is not anticipated by prior art and that it represents a significant improvement or innovation in the field[5].

Global Trends and Comparisons

The USPTO data indicates that the pharmaceutical and biotechnology sectors are among the most active in terms of patent filings. The trend of increasing patent activity in these fields reflects the ongoing research and development aimed at addressing critical health issues like hypertension and hyperkalemia[1].

Economic and R&D Implications

R&D Investment

The development of such patents often involves significant R&D investment. Companies in the pharmaceutical industry, particularly those in the computer and electronics manufacturing sector, report high levels of domestic R&D performance, which is reflected in the number of patents they receive[1].

Market Impact

Patents like US 11,123,363 can have a substantial market impact by providing new treatment options for patients. They also influence the competitive landscape by granting exclusive rights to the patent holders, allowing them to recoup their R&D investments and drive further innovation.

Legal and Regulatory Aspects

Inventorship

Determining the true and only inventors is crucial in patent law. The Court of Appeals for the Federal Circuit has emphasized the importance of correctly identifying inventors to avoid legal disputes and ensure that the patent rights are properly assigned[5].

Patent Validity and Litigation

Patents are subject to various legal challenges, such as obviousness-type double patenting or lack of written description. The case of Allergan USA, Inc. v. MSN Laboratories Private Ltd. highlights the complexities and legal battles that can arise over patent validity[2].

Conclusion and Future Directions

The United States Patent 11,123,363 represents a significant advancement in the treatment of hypertension and hyperkalemia. Understanding the scope, claims, and broader patent landscape is essential for both the pharmaceutical industry and healthcare professionals.

Key Takeaways

  • Novel Composition and Methods: The patent introduces new potassium-binding agents and methods for treating hypertension and hyperkalemia.
  • Competitive Landscape: The patent is part of a highly competitive field with significant R&D investments.
  • Legal and Regulatory Considerations: Correct inventorship and patent validity are critical to maintaining the patent's integrity.
  • Market Impact: The patent can significantly influence treatment options and market dynamics.

Frequently Asked Questions (FAQs)

1. What is the primary focus of United States Patent 11,123,363?

The primary focus is on methods and compositions for treating hypertension and hyperkalemia using potassium-binding agents.

2. What are the key components of the potassium-binding agents described in the patent?

The key components include fluoroacrylate and divinylbenzene crosslinked polymers, which are designed to bind potassium ions.

3. How does the patent fit into the broader technological field?

The patent falls within the pharmaceutical and medical treatments field, specifically addressing cardiovascular and renal diseases.

4. What are the economic implications of this patent?

The patent can have significant economic implications by providing new treatment options, influencing market competition, and allowing the patent holder to recoup R&D investments.

5. What legal considerations are important for this patent?

Correct inventorship, patent validity, and potential legal challenges such as obviousness-type double patenting are crucial legal considerations.

Cited Sources

  1. National Science Foundation, "Invention: U.S. and Comparative Global Trends".
  2. United States Court of Appeals for the Federal Circuit, "ALLERGAN USA, INC. v. MSN LABORATORIES PRIVATE LTD.".
  3. United States Patent and Trademark Office, "Patent Claims Research Dataset".
  4. Google Patents, "Potassium-binding agents for treating hypertension and hyperkalemia".
  5. Oregon State University, "Determining Inventorship for US Patent Applications".

More… ↓

⤷  Subscribe


Drugs Protected by US Patent 11,123,363

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-004 Oct 2, 2023 RX Yes No 11,123,363 ⤷  Subscribe TREATMENT OF HYPERKALEMIA ⤷  Subscribe
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-001 Oct 21, 2015 RX Yes No 11,123,363 ⤷  Subscribe TREATMENT OF HYPERKALEMIA ⤷  Subscribe
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-002 Oct 21, 2015 RX Yes Yes 11,123,363 ⤷  Subscribe TREATMENT OF HYPERKALEMIA ⤷  Subscribe
Vifor Pharma VELTASSA patiromer sorbitex calcium POWDER;ORAL 205739-003 Oct 21, 2015 DISCN Yes No 11,123,363 ⤷  Subscribe TREATMENT OF HYPERKALEMIA ⤷  Subscribe
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 11,123,363

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2013329451 ⤷  Subscribe
Australia 2018260862 ⤷  Subscribe
Australia 2020294307 ⤷  Subscribe
Brazil 112015007749 ⤷  Subscribe
Canada 2886788 ⤷  Subscribe
China 104822383 ⤷  Subscribe
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.